Everstar Asset Management LLC Increases Position in Aquestive Therapeutics, Inc. $AQST

Key Points

• Everstar Asset Management LLC has increased its stake in Aquestive Therapeutics by 38.7%, owning a total of 300,000 shares valued at approximately $870,000.
• Aquestive Therapeutics reported an EPS of ($0.14), surpassing estimates, but its revenue of $10 million fell short of analyst expectations.
• Analysts have positive outlooks for the stock, with a consensus rating of "Buy" and an average target price of $10.14.

Everstar Asset Management LLC grew its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 38.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 300,000 shares of the company's stock after buying an additional 83,777 shares during the period. Everstar Asset Management LLC owned 0.30% of Aquestive Therapeutics worth $870,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of AQST. Pale Fire Capital SE boosted its holdings in shares of Aquestive Therapeutics by 154.1% in the 1st quarter. Pale Fire Capital SE now owns 1,335,684 shares of the company's stock valued at $3,873,000 after buying an additional 809,928 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Aquestive Therapeutics by 905.2% in the 4th quarter. Bank of America Corp DE now owns 690,284 shares of the company's stock valued at $2,457,000 after buying an additional 621,614 shares in the last quarter. Nuveen LLC acquired a new position in shares of Aquestive Therapeutics in the 1st quarter valued at $686,000. Harvey Capital Management Inc. boosted its holdings in shares of Aquestive Therapeutics by 86.8% in the 1st quarter. Harvey Capital Management Inc. now owns 499,570 shares of the company's stock valued at $1,449,000 after buying an additional 232,180 shares in the last quarter. Finally, Stonepine Capital Management LLC acquired a new position in shares of Aquestive Therapeutics in the 4th quarter valued at $570,000. Institutional investors and hedge funds own 32.45% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on AQST. Zacks Research upgraded shares of Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 13th. Oppenheimer upped their target price on shares of Aquestive Therapeutics from $7.00 to $8.00 and gave the company an "outperform" rating in a report on Monday, September 8th. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, June 17th. Finally, Lifesci Capital upgraded shares of Aquestive Therapeutics to a "strong-buy" rating in a report on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Aquestive Therapeutics presently has an average rating of "Buy" and a consensus price target of $10.29.

Aquestive Therapeutics Trading Up 2.0%

AQST stock traded up $0.10 on Friday, hitting $5.05. The company's stock had a trading volume of 2,676,107 shares, compared to its average volume of 2,286,885. The firm has a 50 day moving average of $4.12 and a two-hundred day moving average of $3.32. Aquestive Therapeutics, Inc. has a 1 year low of $2.12 and a 1 year high of $5.80. The stock has a market cap of $503.61 million, a price-to-earnings ratio of -7.21 and a beta of 1.82.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. The business had revenue of $10.00 million during the quarter, compared to analysts' expectations of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Insiders Place Their Bets

In other Aquestive Therapeutics news, insider Peter E. Boyd sold 15,000 shares of the company's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $5.30, for a total transaction of $79,500.00. Following the completion of the transaction, the insider owned 288,323 shares in the company, valued at approximately $1,528,111.90. This represents a 4.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Cassie Jung sold 62,180 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $5.00, for a total transaction of $310,900.00. Following the transaction, the chief operating officer owned 283,346 shares of the company's stock, valued at approximately $1,416,730. The trade was a 18.00% decrease in their position. The disclosure for this sale can be found here. 8.35% of the stock is currently owned by corporate insiders.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.